ALS defeats gabapentin: Reflections on another failed treatment

Neurology

Volumn 56, Issue 7, 2001, Pages 826-827

  McDermott, Michael P ^a,c   Rowland, Lewis P ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Department of Orthopaedic Surgery   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; GLUTAMATE RECEPTOR ANTAGONIST; RILUZOLE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTIFICIAL VENTILATION; CLINICAL TRIAL; EDITORIAL; HUMAN; MUSCLE STRENGTH; PRIORITY JOURNAL; QUALITY OF LIFE; SPASTICITY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0035836669     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.56.7.826     Document Type: Editorial

References (8)

1. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis
2. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis
3. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis
4. Novel drug development for amyotrophic lateral sclerosis
5. Application of high-throughput screening techniques to drug discovery
6. Riluzole for the treatment of amyotrophic lateral sclerosis: Too soon to tell
7. Consensus guidelines for the design and implementation of clinical trials in ALS
8. The Q-TWiST method